Prolongation of QTc interval and antipsychotics.
Taylor
David M
DM
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016757:Death, Sudden, Cardiac / Q000209:etiology / Q000517:prevention & control; D004334:Drug Administration Schedule; D004348:Drug Labeling / Q000592:standards; D016903:Drug Monitoring; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced* / Q000517:prevention & control; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use
D014150:Antipsychotic Agents; D010879:Piperazines; D013844:Thiazoles; C092292:ziprasidone; D006220:Haloperidol; D018967:Risperidone